EXIGENCE TECHNOLOGIES UK LTD

Their core work

Exigence Technologies is a London-based SME specialising in advanced antimicrobial coating technology for hard surfaces, operating under their SymbiCoat brand. Their core innovation is a rechargeable N-Halamine coating system that combines two different antimicrobial mechanisms to deliver sustained, high-efficacy surface protection. The technology targets environments where surface hygiene is critical — most likely food processing, healthcare, or public infrastructure — as evidenced by their classification under the EU's Food and Health research pillar. They moved from early-stage proof-of-concept through to commercial-scale development entirely within the EU's SME Instrument programme, suggesting a company built around bringing a single, well-defined proprietary technology to market.

What they specialise in

How they've shifted over time

Exigence's H2020 history is a single, focused technology journey rather than a broadening research agenda. In 2016 they established feasibility for their dual-mechanism biocide concept (Phase 1), and by 2017 they had secured Phase 2 funding to scale SymbiCoat into a rechargeable N-Halamine product for hard surfaces — showing disciplined, linear progression on one technology. There is no evidence of pivot or diversification: the same brand name, the same technical approach, and the same application domain appear in both projects. This suggests a company that is refining and commercialising rather than exploring new directions.

Exigence appears to be on a commercialisation trajectory with SymbiCoat — having completed Phase 2 by 2019, any future engagement would likely be in licensing, manufacturing partnerships, or sector-specific deployment rather than further basic R&D.

How they like to work

Exigence has acted as project coordinator in both of their H2020 projects, indicating they are comfortable leading funded initiatives rather than joining as a supporting partner. Their consortium footprint is very small — just two unique partners across two countries — which suggests they work in tight, focused teams around a proprietary technology rather than in open, multi-stakeholder consortia. This is consistent with an SME protecting and commercialising a core IP asset: they lead, they control the technology, and they bring in only the partners they need.

Exigence's collaboration network is minimal — two unique partners across two countries, reflecting the SME Instrument's typical structure where a single company drives its own technology commercialisation with lean support. There is no evidence of a broad or recurring partner network.

What sets them apart

Exigence holds what appears to be proprietary IP in rechargeable N-Halamine antimicrobial coating technology — a specific and relatively uncommon chemistry in the surface hygiene space. Their successful completion of both SME Instrument phases means they have passed EU-level scientific and commercial due diligence twice, which is a meaningful credibility signal for potential industry or distribution partners. For a consortium builder, they offer a defined technology asset with demonstrated development maturity rather than broad research capacity.

Highlights from their portfolio

• SymbiCoat (Phase 2)
  With €1,045,144 in EC funding, this is Exigence's flagship project — a full SME Instrument Phase 2 award for scaling rechargeable N-Halamine antimicrobial coating technology toward market entry.
• SymbiCoat (Phase 1)
  The Phase 1 feasibility project that secured the original proof-of-concept validation for combining two antimicrobial mechanisms, enabling the subsequent larger Phase 2 award.